Mural nodules protruding into the lumen and intraluminal air serve as significant predictors of neuroendocrine tumors in patients with acute appendicitis. In a study involving 1,150 patients, those with neuroendocrine tumors exhibited a mural nodule prevalence of 53.3% sensitivity and 95.8% specificity, while intraluminal air showed 53.3% sensitivity and 76.7% specificity. Incorporating these imaging indicators […]
Category: Sarcoma & rare tumors
New tool predicts liver metastasis risks in neuroendocrine tumors
A novel Liver Metastasis Score (LMS) effectively predicts liver metastasis risk for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) post-surgery. Among 724 patients studied, 9.1% developed liver metastasis, significantly impacting survival rates (63.6% vs. 95.8% for no metastasis). Key risk factors identified include Ki-67 index, vascular invasion, lymph node metastases, and absence of adjuvant therapy. The […]
Machine learning model predicts malignant potential of gastric tumors
A novel machine-learning model effectively predicts the malignant potential of gastric gastrointestinal stromal tumors (GISTs), identifying key risk factors such as endoscopic ultrasound features, tumor margin clarity, diameter, and monocyte-to-lymphocyte ratio. Tested with 318 patients, the logistic classification model achieved high performance with area under the curve values of 0.919 and 0.925 for training and […]
High preoperative HbA1c levels correlate with poorer outcomes in GEP-NET patients
Higher preoperative glycosylated hemoglobin A1C (HbA1c) levels significantly affect long-term outcomes in patients undergoing resection for nonfunctional gastroenteropancreatic neuroendocrine tumors (GEP-NETs). A study involving 190 patients revealed that those with HbA1c ≥ 6.5% experienced increased complications and markedly reduced median overall survival (89.8 months vs. not reached for low HbA1c). This association highlights the need […]
Surgery improves outcomes in metastatic neuroendocrine tumors
Evidence suggests that surgical intervention, prior to peptide receptor radionuclide therapy, significantly enhances progression-free survival for patients with metastatic gastroenteropancreatic neuroendocrine tumors. In a study of 89 well-matched patients, those who underwent surgery had a median progression-free survival of 26.1 months, compared to 15.6 months in the no-surgery group (p = .04). Furthermore, liver debulking […]
EUS-FNA/B shows strong diagnostic performance for PANNETs
A meta-analysis involving 2,978 patients confirms that endoscopic ultrasound-guided fine needle acquisition (EUS-FNA/B) is an effective method for diagnosing and pre-operatively grading pancreatic neuroendocrine tumors (PANNETs). The overall concordance rate with surgical grading was 0.77, with a notable increase in the G1 subgroup (0.88). Notably, fine needle biopsy (FNB) outperformed fine needle aspiration (FNA) in […]
Wide hot snare polypectomy outperforms other methods for small tumors
In a study assessing salvage treatments for rectal neuroendocrine tumors (RNETs) under 10 mm, wide hot snare polypectomy (WHSP) showed superior outcomes. Of 121 patients analyzed, WHSP achieved an impressive 72.7% R0 resection rate compared to other methods. With a focus on effectiveness and safety, WHSP emerged as a rapid and straightforward approach for these […]
Inadequate surgical treatment affects non-functioning pancreatic neuroendocrine tumours.
A retrospective study of 384 patients undergoing surgery for non-functioning pancreatic neuroendocrine tumours revealed that 40% received potentially inadequate treatment. Of these, 34% experienced potential overtreatment while 6% were potentially undertreated. Key predictors of overtreatment included smaller tumour sizes and earlier surgical intervention, while larger tumour diameter indicated potential undertreatment. Patients facing undertreatment exhibited significantly […]
EUS and Surgery Enhance Treatment Options for Pancreatic Tumors
The review highlights the evolving role of endoscopic ultrasound (EUS) in managing pancreatic neuroendocrine tumors (PanNETs), addressing their increasing incidence and associated diagnostic and therapeutic challenges. EUS has advanced from solely a diagnostic tool to facilitating minimally invasive locoregional therapies. Surgical intervention remains paramount, especially for localized, low-grade PanNETs larger than 2 cm. Although not […]
Subgrading of G2 Pancreatic Neuroendocrine Tumors Reveals Behaviorally Distinct Subsets
Subgrading G2 pancreatic neuroendocrine tumors into 2A (Ki67 3% to < 10%) and 2B (10% to ≤ 20%) identifies distinct subsets with different metastasis rates and aggressiveness. G2B cases show significantly higher rates of liver/distant metastasis, lymph node metastasis, and histopathologic signs of aggressiveness compared to G2A. G2B tumors behave similarly to G3, suggesting they […]